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ABSTRACT
Introduction: Magnesium is a critical cofactor in 
numerous enzymatic reactions. Diabetic patients 
and obese subjects are often reported to have 
intracellular magnesium ([Mg2+]i) deficiency. We 
studied the change of [Mg2+]i in obese children 
and children with type 2 diabetes mellitus (DM2) 
after educational intervention or treatment. 
Methods: A total of 25 subjects were included: 13 
with simple obesity (10 male, 3 female; mean age 
16±8 years, intervention period 1.0±0.6 years), 12 
with DM2 (8 male, 4 female; mean age 15±3 years, 
medication period 1.1±0.7 years), and 16 controls 
(8 male, 8 female; mean age 17±7 years). By using 
a fluorescent probe, mag-fura-2, we examined 
the basal and insulin-stimulated [Mg2+]i 
of platelets in the blood. Plasma leptin, ghrelin, 
adiponectin, and resistin levels were determined 
with the use of enzyme-linked immunosorbent 
assay (ELISA). Results: Mean basal [Mg2+]i was 
lower in the obesity (160±65 μmol/L) and DM2 
groups (140±30 μmol/L) compared with the 
control group (330±28 μmol/L). The elevated 
[Mg2+]i after insulin stimulation was also lower 
in these two groups (420±140 μmol/L, and 
330±70 μmol/L, respectively) compared with 
the control group (690±270 μmol/L). In the 
DM2 group, the basal [Mg2+]iwas significantly 
increased after treatment, while in the obesity 
group, stimulated [Mg2+]i was increased after 
intervention.  Conclusion: Platelet [Mg2+]i 
increased after intervention in children with 
obesity or DM2.
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INTRODUCTION
Magnesium deficiency occurs in patients 
with diabetes and vascular diseases.1,2 We and 
other investigators have reported that insulin 
can mediate intracellular magnesium ([Mg2+]i) 
in platelets.3,4 Platelets are often used in
the study of cellular cation metabolism in diseases5
because they are readily available for study and 
are thought to share a number of features with 
vascular smooth muscle cells. Human platelets 
have been shown to have insulin receptors with 
characteristics similar to those in other cells.6
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Medical University. Written informed parental 
consent was obtained before recruitment.
Educational Intervention and Treatment
We educated the children and parents in a 
formal program of intensive lifestyle modification 
through anticipatory guidance about healthy 
dietary  and  activity  habits.  According  to 
information  from  the  American  Academy  of 
Pediatrics,12 we prescribed and supported healthy 
eating habits such as avoiding the consumption 
of calorie-dense, nutrient-poor foods (for example, 
sweetened beverages, sports drinks, fruit drinks 
and juices, most “fast food” types, and calorie-
dense snacks). We prescribed eating timely, regular 
meals, particularly breakfast. We prescribed 30 
minutes  of  daily  moderate  physical  activity, 
such as walking briskly or riding a bicycle. We 
supported a decrease in time spent in sedentary 
activities, such as watching television, playing 
video games, or using computers for recreation. 
Screen time was advised to be limited to 1-2 hours 
per day. No obesity subject was treated with any 
medication,  including  magnesium,  and  none 
showed any evidence of endocrine malfunction 
or recent use of drugs that might potentially 
alter electrolyte balance. The patients with DM2 
were treated with metformin (250-750 mg orally 
twice daily), glybencramide 2.5 mg twice daily, 
and subcutaneous insulin 0.2-0.4 units/kg body 
weight twice daily, in combination with lifestyle 
modification.
Platelet Preparation
Blood samples were collected with citrate acid 
buffer and kept at 4°C. Platelets were isolated 
as previously described.13 Approximately 5 mL 
of blood was taken and added to 3.8% (w/v) 
acid citrate buffer (10:1, v/v) then centrifuged 
at 200 g for 10 minutes at room temperature. 
The  association  between  magnesium 
deficiency and insulin resistance in children has 
been reported previously.7 However, there are 
few papers that report [Mg2+]i and its role in the 
pathogenesis of insulin resistance.8
Previously, we have reported that [Mg2+]i 
is lower in children with diabetes mellitus and 
obese children.9 We hypothesized that [Mg2+]i 
increases in accordance with improvement of 
diabetic control in obese children and children 
with type 2 diabetes mellitus (DM2).
METHODS
Subjects
These study groups consisted of children with 
simple obesity or DM2. Diabetes was defined 
using the criteria of the American Diabetes 
Association.10  Consequently,  if  the  diabetes 
criteria were met, the patient was considered 
to have DM2 regardless of body mass index 
(BMI). Height was measured to an accuracy of 
0.1 cm and weight to 0.1 kg. Blood pressure was 
measured using a portable sphygmomanometer 
after the subject had rested in the sitting position 
for at least 5 minutes. A child was diagnosed as 
obese if his or her BMI was at least in the 95th 
percentile for age and sex or was over 25 kg/m2. 
The percentage overweight definition was based 
on the percentage of a reference weight that is 
based on age, sex, and height.11 The control group 
consisted of subjects with normal blood pressure 
and a negative family history of diabetes mellitus. 
Samples from the control group were obtained 
once for the [Mg2+]i measurements.
Ethical Considerations
This  study  was  in  compliance  with  the 
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the methods of Ng et al.16 Insulin was dissolved 
in deionized water. A total of 25 μL of insulin was 
added to 2.5 mL of platelet suspension. The final 
concentration of insulin was 0.72 nmol/L. 
Enzyme-Linked Immunosorbent Assay
Plasma for enzyme-linked immunosorbent 
assay (ELISA) was separated immediately, stored 
at –80°C, and thawed only once before analysis. 
Plasma glucose levels were measured by the 
glucose oxidase methods. Plasma leptin levels 
were determined with the use of a commercially 
available  ELISA  kit  (Immuno-Biological 
Laboratories Co., Ltd., Gunma, Japan) with a 
detection limit of 195 ng/L (intra-assay and 
interassay coefficient of variations [CVs] of 6.9% 
and 7.7%, respectively). A plasma adiponectin 
assay  was  performed  using  a  commercially 
available ELISA kit (R&D System Inc. Minneapolis, 
MN, USA) with a detection limit of 0.246 ng/mL 
(intra-assay and interassay CVs of 3.4% and 
6.8%, respectively). Plasma resistin assay was 
performed  using  a  commercially  available 
ELISA kit (R&D System Inc. Minneapolis, MN, 
USA) with a detection limit of 0.026 ng/mL 
(intra-assay and interassay CVs of 5.3% and 
8.2%,  respectively).  Plasma  desacyl  ghrelin 
concentrations were determined with the use of 
a commercially available ELISA kit (Mitsubishi 
Kagaku  Iatrons,  Inc.,  Tokyo,  Japan)  with  a 
detection limit of 1.08 fmol/mL (intra-assay and 
interassay CVs of 5.3% and 9.8%, respectively).
Insulin concentrations were measured by 
means of a chemiluminescence immunological 
assay  (Chemilumi  Insulin;  Kyowa  Medics, 
Tokyo, Japan).
Chemicals
All chemicals were purchased from Sigma 
Chemical  Co.  (St.  Louis,  MO,  USA),  unless 
The platelet-rich plasma was decanted, further 
centrifuged at 1000 g for 10 minutes, and the 
cells were washed three times in Hepes buffer 
solution (HBS) containing NaCl 140 mM, KCl 
5 mM, glucose 25 mM, MgCl2 1 mM, NaH2PO4 
1 mM, 2-[4-(2-hydroxyethyl)-1-piperazinyl] 
ethanesulfonic acid (HEPES) 25 mM (pH 7.2), 
and  ethylene  glycol-bis(2-aminoethylether)-
N,N,N’,N’-tetraacetic acid (EGTA) 0.2 mM. EGTA 
was  omitted  from  the  third  washing,  and 
0.1%  fatty-acid  free  bovine  serum  albumin 
was added. Platelets were counted in a Celltac 
counter (Nihon Kohden, Tokyo, Japan). Unless 
otherwise indicated, platelets were suspended in 
HBS at a concentration of 2-3×107 platelets/mL. 
Platelets were studied within 4 hours after blood 
drawing.
Measurements of Intracellular [Mg2+]i 
Concentrations
Ionic [Mg2+]i concentrations were measured with 
a Hitachi F-2000 fluorescence spectrophotometer 
(Hitachi Instruments, Tokyo, Japan) by using an 
Mg-specific fura-2 probe as described by Raju et al.14 
A 2 μmol/L quantity of mag-fura-2/acetoxymethyl 
dye (fura dye) was added to the platelet suspension 
and incubated at 37°C for 30 minutes. After loading 
of the dyes, the platelets were washed twice with 
HBS, the fura dyes were removed by centrifugation, 
and the platelets were resuspended in HBS. The 
excitation wavelengths were set at 335/370 nm, 
and the emission wavelength was 510 nm. Each 
intracellular ionic concentration was calculated as 
described previously,14,15 by using the dissociation 
constant Kd=1500 μM. The maximum intensities 
were determined by disrupting the cells with 
0.1% Triton in the presence of 30 mM MgCl2. The 
minimum intensities were the values determined 
in the presence of 60 mM EDTA. Manganese 
(II) chloride (0.05 mM) was used to quench the 
fluorescence from extracellular dye according to 28 Diabetes Ther (2010)  1(1):25-31.
stated otherwise. Mag-fura-2/acetoxymethyl was 
purchased from Molecular Probes (Eugene, OR, 
USA).
Statistical Analysis
Data  were  expressed  as  the  mean±SD. 
Statistical significance was assessed using analysis 
of variance (ANOVA). Outcome variables were 
compared between the subgroups (obesity, DM2, 
and control) using t tests. A value of P<0.05 was 
considered significant. All statistical analyses 
were performed using StatView software (SAS 
Institute Inc., Cary, NC, USA).
RESULTS
Subjects
The  obesity  study  group  consisted  of 
13  subjects  with  simple  obesity  (10  male, 
3 female; mean age 16±8 years, intervention 
period 1.0±0.6 years). The DM2 group consisted 
of 12 subjects with DM2 (8 male, 4 female; mean 
age 15±3 years, medication period 1.1±0.7 years). 
Five patients were treated with metformin, one 
with glybencramide, and two with insulin in 
combination with lifestyle modification. The 
control group consisted of 16 subjects (8 male, 
8 female; mean age 17±7 years).
Profile of Each Group
A profile of the study subjects is shown in 
Table 1. No statistical differences among the 
groups were observed for serum magnesium. 
No  significant  difference  in  plasma  leptin, 
adiponectin, ghrelin, resistin, and insulin levels 
existed between the obesity and DM2 groups 
(Table 2). Each group did not differ significantly 
in terms of medication or prescription. There was 
no difference of leptin values between genders 
(data not shown).
The Effect of Intervention or Treatment
In the obesity group, body weight, BMI, 
percentage  overweight,  and  blood  pressure 
were decreased after educational prescription. 
Plasma  leptin  and  resistin  were  decreased 
after intervention. Adiponectin and ghrelin 
were increased but not significantly. In the 
DM2  group,  glycated  hemoglobin  (HbA1c), 
mean  glucose,  and  blood  pressure  were 
Table 1. Characteristics of the study participants.
Control Obesity Type 2 DM
n 16 13 12
Male/female 8/8 10/3 8/4
Age, years 17±7 16±8 15±3
Duration of therapy, years – 1.0±0.6 1.1±0.7
BMI, kg/m2 23±6 33±5* 29±7
Systolic blood pressure, mmHg 110±12 130±12 120±13
Diastolic blood pressure, mmHg 70±12 83±19 81±13
Basal [Mg2+]i, μmol/L 330±28 160±65* 140±30*
Stimulated [Mg2+]i, μmol/L 690±270 420±140* 330±70*
Serum Mg, mg/dL 2.0±0.1 2.0±0.1 1.9±0.1
BMI=body mass index; DM=diabetes mellitus; Mg=magnesium; [Mg2+]i=intracellular magnesium.
*P<0.01 vs. control.29 Diabetes Ther (2010)  1(1):25-31.
decreased after treatment. But there was no 
significant difference in adipocytokine levels after 
treatment (Table 2).
[Mg2+]i
In the obesity and DM2 groups, basal [Mg2+]i 
was significantly lower than in the control group 
(Table 1). To examine the response of platelets 
to  insulin,  we  studied  [Mg2+]i  after  insulin 
stimulation. At 60 seconds after stimulation 
with 0.72 nmol/L of insulin, stimulated [Mg2+]i 
in the obesity and DM groups was lower than in 
the control group (Table 1). 
Change in [Mg2+]i After Intervention or 
Treatment
In  the  DM2  group,  the  basal  [Mg2+]i 
significantly increased after treatment. However, 
there was no difference between before and after 
stimulated [Mg2+]i levels with insulin (Table 2). 
Stimulated [Mg2+]i decreased after treatment in 
only two of the 12 subjects. However, in all DM2 
subjects, basal [Mg2+]i increased after treatment.
In  the  obesity  group,  stimulated  [Mg2+]i 
increased after treatment. However, there was no 
difference in basal [Mg2+]i levels between groups 
before and after intervention (Table 2). Basal 
[Mg2+]i decreased after treatment in only one 
subject. In all obese subjects, stimulated [Mg2+]i 
increased after treatment.
DISCUSSION
Previously, we reported that children with 
diabetes and obesity have [Mg2+]i deficiency.9 
We further tested whether [Mg2+]i deficiency 
may improve after management. After a short 
educational program or treatment for obesity 
and DM2, we found that [Mg2+]i increased in 
accordance with the improvement of diabetes 
Table 2. Effect of intervention or treatment.
Obesity Type 2 DM
Before After Before After
Body weight, kg 82±24 79±21 73±20 79±21
BMI, kg/m2 33±5 32±4 29±7 30±8
HbA1c, % 5.0±0.3 5.1±0.3 7.8±3.7 5.9±1.5
Basal [Mg2+]i, μmol/L 160±65 210±80 140±30 180±40†
Stimulated [Mg2+]i, μmol/L 420±140 540±280* 330±70 360±75
Serum Mg, mg/dL 2.0±0.1 2.0±0.1 1.9±0.1 2.0±0.2
Glucose, mg/dL 95±8 110±40 190±100 150±50
Immunoreactive insulin, μU/mL 52±32 96±130 64±40 68±62
Leptin, pg/mL 7100±4100 5800±2600 2600±3700 5700±4400
Adiponectin, μg/mL 1.88±0.34 4.06±2.61 2.61±1.21 2.60±1.16
Ghrelin, fmol/mL 45.3±35.0 49.0±29.0 33.1±18.6 33.8±9.2
Resistin, ng/mL 17.8±3.3 7.5±6.1 5.9±2.6 4.2±2.2
BMI=body mass index; DM=diabetes mellitus; HbA1c=glycated hemoglobin; Mg=magnesium; 
[Mg2+]i=intracellular magnesium.
*P<0.05 vs. before intervention or treatment.
†P<0.01 vs. before intervention or treatment.30 Diabetes Ther (2010)  1(1):25-31.
control  and  obesity.  In  this  study,  neither 
magnesium supplementation nor the test for 
dietary magnesium intake were adopted.
Leptin, ghrelin, adiponectin, and resistin are 
thought to take part in the regulation of energy 
metabolism. These hormones have important 
roles  in  energy  homeostasis,  glucose,  and 
lipid metabolism.17 In this study, however, no 
significant change to levels of these hormones 
was observed after intervention.
In the DM2 group, in chronic diabetic states 
hyperglycemia may induce a decline of [Mg2+]i 
levels. The [Mg2+]i level was much lower in the DM2 
group compared with the obesity group. Several 
factors are reported to have effects on [Mg2+]i. 
Hyperglycemia  may  also  have  an  effect  on 
magnesium transport and induce a decline of 
[Mg2+]i. However, there was no difference between 
before and after levels of stimulated [Mg2+]i in the 
DM2 group. The in-vitro glucose-independent 
ionic effects of insulin are blunted in cells with 
a reduced basal [Mg2+]i level.18,19 Corsonello et al. 
reported that the decrease in serum magnesium 
concentration is correlated with fasting blood 
glucose, HbA1c, albumin excretion, and duration 
of diabetes.20 In our study, there was no correlation 
between plasma glucose and basal [Mg2+]i levels. In 
addition, we did not find any correlation between 
HbA1c levels and [Mg2+]i levels. The reason for this 
discrepancy is considered to be the short study 
period. One of the study limitations is that the 
study group was fairly small, which might explain 
some of the negative findings. Further studies will 
be needed to consider this limitation.
In  the  obesity  group,  we  did  not  find  a 
significant difference in basal [Mg2+]i  levels 
before  and  after  educational  prescription. 
However, in the obesity group, [Mg2+]i levels in 
response to insulin stimulation increased after 
treatment. The difference between the change 
of [Mg2+]i levels in the two groups may be due to 
the following reasons: (1) the grade of deficiency 
in [Mg2+]i levels was different in these groups 
([Mg2+]i levels in the DM2 group were much 
lower compared to that in the obesity group), 
(2) the duration of the study was short — longer 
treatment may have elevated basal [Mg2+]i levels 
in the obesity group and/or stimulated [Mg2+]i 
levels in the DM2 group.
Insulin has specific ionic effects that stimulate 
the transport of magnesium from extracellular to 
intracellular components, thus increasing [Mg2+]i.3 
The  mechanism  by  which  insulin  acutely 
increases [Mg2+]i is still unclear. Insulin regulates 
cellular Mg2+ metabolism in part via an increase 
in the affinity for Na+ of the Na+/Mg2+ exchange 
and phosphatidylinositol 3-kinase activation.21 In 
turn, [Mg2+]i is critical in the phosphorylation of 
the tyrosine kinase of the insulin receptor as well 
as all other protein kinases. Magnesium deficiency 
may result in disorders of tyrosine kinase activity 
on the insulin receptor and events related to the 
development of post-receptor insulin resistance.22 
The lower the basal [Mg2+]i, the greater the amount 
of insulin required to metabolize the same glucose 
load, indicating decreased insulin sensitivity.23
In obesity, platelet [Mg2+]i is decreased before 
the poor insulin reactivity occurs in the platelets. 
The present study was conducted on the basis 
of the hypothesis that decreased [Mg2+]i might 
underlie the initial pathophysiologic events 
leading to insulin resistance. In addition, [Mg2+]i 
increased in accordance with the improvement 
of diabetic control and obesity. 
CONCLUSION
Platelet  [Mg2+]i  levels  increased  after 
intervention in children with obesity or DM2.
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